Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report

doi:10.3389/fonc.2020.559057

	Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report
	Yang, Zi-yan 1,5,6; Huang, Jia-huan 5,6; Chen, Bo 2; Xu, Chun-wei 3; Lei, Lei 5,6; Wang, Xiao-jia 5,6; Fang, Mei-yu 4
刊名	FRONTIERS IN ONCOLOGY
	2020-10-02
卷号	10
关键词	salivary duct carcinoma tyrosine kinase inhibitor pyrotinib HER2 positive targeted
ISSN号	2234-943X
DOI	10.3389/fonc.2020.559057
通讯作者	Lei, Lei(leilei1241@gmail.com) ; Wang, Xiao-jia(wxiaojia0803@163.com) ; Fang, Mei-yu(fangmy@zjcc.org.cn)
英文摘要	Background:Salivary duct carcinoma (SDC), an aggressive and rare malignancy with poor prognosis, is mostly associated with the overexpression of the androgen receptor (AR) and human epidermal growth factor receptor 2 (HER2). However, limited data are available for the targeting of both HER2 and AR in advanced/metastatic SDC. Case Presentation:A 62-year-old man with advanced SDC accompanied by lung and lymph node metastasis showed disease progression after two lines of chemotherapy and endocrine therapy. Metastatic lesions from the lung biopsy were obtained, and immunohistochemistry (IHC) indicated the overexpression of AR and HER2 (3+). The patient was administered pyrotinib (a pan-ErbB receptor tyrosine kinase inhibitor) and bicalutamide (an androgen receptor antagonist) as a third-line treatment. During the ten months of follow-up, a durable partial response was achieved with this combination. Conclusions:This is the first clinical study to report the successful application of pyrotinib in a patient with advanced SDC. We recommend that pyrotinib and bicalutamide be used as salvage therapy for AR and HER2-positive advanced metastases in SDC, given the favorable response and clinical benefit.
WOS关键词	ANDROGEN-RECEPTOR ; TUMORS ; MANAGEMENT ; PROFILES ; THERAPY ; HER2
WOS研究方向	Oncology
语种	英语
出版者	FRONTIERS MEDIA SA
WOS记录号	WOS:000578251600001
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/104612]
专题	中国科学院合肥物质科学研究院
通讯作者	Lei, Lei; Wang, Xiao-jia; Fang, Mei-yu
作者单位	1.Hangzhou Med Coll, Peoples Hosp, Zhejiang Prov Peoples Hosp, Dept Oncol, Hangzhou, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Pathol, Hangzhou, Peoples R China 3.Nanjing Univ, Med Sch, Affiliated Jinling Hosp, Dept Resp, Nanjing, Peoples R China 4.Univ Chinese Acad Sci, Key Lab Head & Neck Canc Translat Res Zhejiang Pr, Inst Canc Res & Basic Med Sci, Dept Gen Oncol,Chinese Acad Sci,Canc Hosp, Hangzhou, Peoples R China 5.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Dept Breast Oncol, Hangzhou, Peoples R China 6.Chinese Acad Sci, Inst Canc & Basic Med ICBM, Hangzhou, Peoples R China
推荐引用方式 GB/T 7714	Yang, Zi-yan,Huang, Jia-huan,Chen, Bo,et al. Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report[J]. FRONTIERS IN ONCOLOGY,2020,10.
APA	Yang, Zi-yan.,Huang, Jia-huan.,Chen, Bo.,Xu, Chun-wei.,Lei, Lei.,...&Fang, Mei-yu.(2020).Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report.FRONTIERS IN ONCOLOGY,10.
MLA	Yang, Zi-yan,et al."Efficacy of Pyrotinib in HER2-Overexpressing Salivary Duct Carcinoma With Lung Metastasis: A Case Report".FRONTIERS IN ONCOLOGY 10(2020).